


3Helix

Empowering collagen targeting for the diagnosis and treatment of human conditions



What are CHPs?

Collagen is the most abundant protein in mammals. It is the major structural component of almost all organs and tissues. Excessive collagen remodeling is associated with a variety of chronic pathological conditions, such as cancer, arthritis, and fibrosis.


3Helix's **Collagen Hybridizing Peptide (CHP)** is a synthetic peptide that can specifically bind to denatured collagen by structural recognition of exposed alpha-strands. Our *in vivo* CHP is conjugated to a near-infrared dye to enable **accurate and reliable measurements** of collagen turnover in live animal models. CHPs can be used in sub-cutaneous, *in situ*, or intra-venous injections and a single animal can be dosed several times. Multiple images can be taken after a single injection and the fluorescent signal can be quantified using image analysis software, such as ImageJ.

In vivo imaging of nAMD


in collaboration with Roche Ophthalmology

Neovascularized age-related macular degeneration (nAMD) is a condition that affects 17 million people worldwide and is accompanied by subretinal fibrosis. CHPs are able to directly detect fibrotic regions in a laser-induced model for nAMD in an *in vivo* setting and the signal can be easily quantified.

In vivo imaging and *ex vivo* fluorescent immunofluorescence of sulfo-cyanine 7.5 collagen hybridizing peptide (sCy7.5-CHP) binding to remodeling collagen in JR5558 mice. JR5558 mice received targeted or control sCy7.5-CHPs intravenously and were analyzed 5 days later using *in vivo* imaging followed by *ex vivo* IHC. (A) Representative images of JR5558 retinas showing infrared reflectance (IR), fluorescein angiography (FA), and sCy7.5-CHP *in vivo* binding. (B) MFI of control and targeted sCy7.5-CHPs in JR5558 retinas (control, n = 4; targeted, n = 7). (C) Representative images of retinal pigment epithelium (RPE)/choroid flat mounts from JR5558 mice (previously injected with sCy7.5-CHPs) co-stained for sCy3 collagen hybridizing peptide (R-CHP) binding, isolectin B4, and fibronectin.



In vivo imaging of bone destruction in Multiple Myeloma



(A) Micro-CT scans of the spine from the multiple myeloma (MM) mouse showing abundant osteolytic lesions as "hollow spots", in comparison to a normal control. (B) Luciferase bioluminescence showing myeloma cell growth only in the MM mouse. (C) Near-IR CHP images of the MM mouse in (B) and a normal control mouse, demonstrating highly elevated signals in the MM mouse.

Distributed by:


CliniSciences Group

Why Use CHPs

CHPs specifically visualize degraded collagen *in vivo*. Unlike competitor products, such as MMPsense, that detect enzyme activities as an indirect measure, CHP **binds directly to degraded collagen at the molecular level** allowing for accurate visualization of disease states. Our *in vivo* CHPs can be directly injected without pre-activation.

- Superb affinity and signal intensity that can be used for small animal imaging.
- CHP has a strong capability to hybridize with denatured collagen strands *in vivo* by reforming the triple helix.
- CHPs are able to detect actively remodeling collagen in fibrotic conditions over time.
- Our *in vivo* CHP maintains high affinity for denatured collagen without the need for any pre-workup.
- Applicable to all types of collagen in any species with essentially no nonspecific binding

In vivo imaging of chronic kidney disease



CHPs can be used to study a wide variety of diseases states
Subretinal fibrosis nAMD, Kidney fibrosis, Idiopathic pulmonary fibrosis (IPF), Pancreatic cancer, NASH

In Vivo CHPs	SKU	Size
Target-sCy7.5-CHP	INVIVOTGT7.5	3 Doses (8nmole)
Control-sCy7.5-scCHP	INVIVOCTL7.5	3 Doses (8nmole)
sCY7.5 In Vivo Kit	INVIVOKIT7.5	10 Doses Targeted (24nmole), 3 doses control (8nmole)

Distributed by:

CliniSciences Group

CliniSciences Group

Austria

Company: CliniSciences GmbH
Address: Sternwartestrasse 76, A-1180
Wien - Austria
Telephone: +43 720 115 580
Fax: +43 720 115 577
Email: gesterreich@clinisciences.com
Web: <https://www.clinisciences.com>



Belgium

Company: CliniSciences S.R.L
Address: Avenue Stalingrad 52, 1000
Brussels - Belgium
Telephone: +32 2 31 50 800
Fax: +32 2 31 50 801
Email: belgium@clinisciences.com
Web: <https://www.clinisciences.com>



Denmark

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: denmark@clinisciences.com
Web: <https://www.clinisciences.com>



Finland

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: suomi@clinisciences.com
Web: <https://www.clinisciences.com>



France

Company: CliniSciences S.A.S
Address: 74 Rue des Suisses, 92000
Nanterre- France
Telephone: +33 9 77 40 09 09
Fax: +33 9 77 40 10 11
Email: info@clinisciences.com
Web: <https://www.clinisciences.com>



Germany

Company: Biotrend Chemikalien GmbH
Address: Wilhelm-Mausser-Str. 41-43,
50827 Köln - Germany
Telephone: +49 221 9498 320
Fax: +49 221 9498 325
Email: info@biotrend.com
Web: <https://www.biotrend.com>



Iceland

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: island@clinisciences.com
Web: <https://www.clinisciences.com>



Ireland

Company: CliniSciences Limited
Address: Ground Floor, 71 lower Baggot street
Dublin D02 P593 - Ireland
Telephone: +353 1 6971 146
Fax: +353 1 6971 147
Email: ireland@clinisciences.com
Web: <https://www.clinisciences.com>



Italy

Company: CliniSciences S.r.l
Address: Via Maremmana inferiore 378
Roma 00012 Guidonia Montecelio - Italy
Telephone: +39 06 94 80 56 71
Fax: +39 06 94 80 00 21
Email: italia@clinisciences.com
Web: <https://www.clinisciences.com>



Netherlands

Company: CliniSciences B.V.
Address: Krajenhoffstraat 137A,
1018RG Amsterdam, - Netherlands
Telephone: +31 85 2082 351
Fax: +31 85 2082 353
Email: nederland@clinisciences.com
Web: <https://www.clinisciences.com>



Norway

Company: CliniSciences AS
Address: c/o MerVerdi Munkerudtunet 10
1164 Oslo - Norway
Telephone: +47 21 988 882
Email: norge@clinisciences.com
Web: <https://www.clinisciences.com>



Poland

Company: CliniSciences sp.Z.o.o.
Address: ul. Rolmistrza Witolda Pileckiego 67
lok. 200 - 02-781 Warszawa -Poland
Telephone: +48 22 307 0535
Fax: +48 22 307 0532
Email: polska@clinisciences.com
Web: <https://www.clinisciences.com>



Portugal

Company: Quimigen Unipessoal LDA
Address: Rua Almada Negreiros, Lote 5, Loja 14,
2615-275 Alverca Do Ribatejo - Portugal
Telephone: +351 30 8808 050
Fax: +351 30 8808 052
Email: info@quimigen.com
Web: <https://www.quimigen.pt>



Spain

Company: CliniSciences Lab Solutions
Address: C/ Hermanos del Moral 13
(Bajo E), 28019, Madrid - Spain
Telephone: +34 916 750 700
Fax: +34 91 269 40 74
Email: espana@clinisciences.com
Web: <https://www.clinisciences.com>



Sweden

Company: CliniSciences ApS
Address: Oesterbrogade 226, st. 1,
Copenhagen, 2100 - Denmark
Telephone: +45 89 888 349
Fax: +45 89 884 064
Email: [sverige@clinisciences.com](mailto: sverige@clinisciences.com)
Web: <https://www.clinisciences.com>



Switzerland

Company: CliniSciences AG
Address: Fracht Ost Flughafen Kloten
CH-8058 Zürich - Switzerland
Telephone: +41 (044) 805 76 81
Fax: +41 (044) 805 76 75
Email: switzerland@clinisciences.com
Web: <https://www.clinisciences.com>



UK

Company: CliniSciences Limited
Address: 11 Progress Business center, Whittle
Parkway, SL1 6DQ Slough- United Kingdom
Telephone: +44 (0)1753 866 511
or +44 (0) 330 684 0982
Fax: +44 (0)1753 208 899
Email: uk@clinisciences.com
Web: <https://www.clinisciences.com>



USA

Company: CliniSciences LLC
Address: c/o Carr Riggs Ingram,
500 Grand Boulevard, Suite 210 Miramar
Beach, FL 32550- USA
Telephone: +1 850 650 7790
Fax: +1 850 650 4383
Email: usa@clinisciences.com
Web: <https://www.clinisciences.com>

